Review Article

Drug Induced Liver Injury (Dili) and Non Alcoholic Fatty Liver Disease (Nafld)

Goran Bokan
University Clinical Center of Republic of Srpska, Bośnia i Hercegowina
* Corresponding author
Nikola Malešević
University Clinical Center of Republic of Srpska, Bośnia i Hercegowina
Anna Licata
University of Palermo Medical School, Italy
Zoran Mavija
University Clinical Center of Republic of Srpska, Bośnia i Hercegowina
DOI icon 10.24018/ejmed.2020.2.4.439

Read Counter
1157

Downloads
841

Citations

Share

Article Sidebar

Submitted 2020-08-15
Published 2020-08-29

Read counter = 1157 times

Table of Contents

Article Main Content

This review article includes a review of the latest literature searched on PubMed in the field of hepatotoxicity caused by drugs that have a wide daily application. The concept of the review article consists of several parts dealing with the definition of drugs induced liver injury - DILI, diagnostic challenges related to it, and the clinical spectrum of liver disease, with an emphasis on the development of nonalcoholic fatty liver disease - NAFLD and review of drugs involved in formation of NAFLD.

Keywords: DILI, NAFLD, RUCAM, hepatotoxicit

References

  1. Bjornsson ES. Drug-induced liver injury: an overview over the most critical compound. ArchToxicol 2015; 89: 327-334.
    DOI  |   Google Scholar
  2. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.
     Google Scholar
  3. Licata A, Minissale MG, Caruso V, Craxi A. A focus on epidemioogy of drug-induced liver injury: analysis of a prospective cohort: Eur Rev Med Pharmacol Sci. 2017; 21(1 Suppl): 112-121.
     Google Scholar
  4. Björnsson E, Olsson R. Suspected drug induced liver fatalities reported to the WHO database. Dig Liv Dis 2006;38:33-8.
    DOI  |   Google Scholar
  5. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatology 2015; 63:503-14.
    DOI  |   Google Scholar
  6. Kim SH, Naisbitt DJ. Update on Advances in Research of Idiosyncratic Drug Induced Liver Injury. Allergy Asthma Immunol Res 2016;8:3-11.
    DOI  |   Google Scholar
  7. Björnsson E. Drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010; 32: 3-13.
    DOI  |   Google Scholar
  8. Zaffani S, Cuzzolin L, Benoni G: Herbal products: behaviours and beliefs among Italian women. Pharmacoepidemiol Drug Saf 2006; 15: 354-359.
    DOI  |   Google Scholar
  9. Gordon DW, Rosenthal G, Hart J, Sirota R, Baker AL. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA 1995; 273: 489-490.
    DOI  |   Google Scholar
  10. Watkins, P.B., Seligman, P.J., Pears, J.S. et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008; 48: 1680–1689.
    DOI  |   Google Scholar
  11. Chalasani, N. and Bjornsson, E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010; 138: 2246–225.
    DOI  |   Google Scholar
  12. Russo, M.W. and Watkins, P.B. Are patients with elevated liver tests at increased risk of drug-induced liver injury?. Gastroenterology. 2004; 126: 1477–1480.
    DOI  |   Google Scholar
  13. Abboud G., Kaplowitz N. Drug-Induced Liver Injury. Drug Saf 2007; 30: 277-94.
    DOI  |   Google Scholar
  14. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, William ML, Yuen NA et al. Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Evenets in VigiBase Drug Sad 2010;33:503-22.
    DOI  |   Google Scholar
  15. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010; 115:307–21.
    DOI  |   Google Scholar
  16. Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin North Am. 2008;92:761–94.
    DOI  |   Google Scholar
  17. Lewis JH, Ahmed M, Shobassy A, Palese C. Drug-induced liver disease. Curr Opin Gastroenterol 2006; 22:223-33.
    DOI  |   Google Scholar
  18. Chalasani P, Hayashi P, Bonkovsky H, Navarro V, Lee W. ACG Clinical Guideline: the diagnosis andmanagement of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol 2014; 109: 950-966.
    DOI  |   Google Scholar
  19. Food and Drug Administration. Drug-induced livery injury: premarketing clinical evaluation. In: Guidance for industry. 2009.
     Google Scholar
  20. Jalan, R., Gines, P., Olson, J.C. et al. Acute-on chronic liver failure. J Hepatol. 2012; 57: 1336–1348.
    DOI  |   Google Scholar
  21. Navarro VJ, Senior JR. Drug related hepatotoxicity. N Engl J Med 2006; 354: 731-739.
    DOI  |   Google Scholar
  22. Reuben A, Koch DG, Lee WM. Drug induced acute liver failure: results of a US multicenter, prospective study. Hepatology 2010; 52: 2065-2076.
    DOI  |   Google Scholar
  23. Danan G. The Roussel Uclaf Causality Assessment Method (RUCAM) score is based upon a modification of the original scoring system of the Council for International Organizations of Medical Sciences (CIOMS) and supported by Roussel Uclaf Pharmaceuticals. Consensus Meetings on: causality assessment of drug-induced liver injury. J Hepatol 1988; 7: 132-136.
     Google Scholar
  24. Danan G, Benichou C. Causality assessment of adverse reaction to drugs--A novel method based on the conclusions of international consensus meeting: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
     Google Scholar
  25. Benichou, Danan G, Flahault A. Causality assessment of adverse reactions to drugs. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336.
     Google Scholar
  26. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology 1997; 26: 664-669.
    DOI  |   Google Scholar
  27. Chalasani N, Fontana RJ, Bonkovsky Hl. Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.
    DOI  |   Google Scholar
  28. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336.
     Google Scholar
  29. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1). doi: 10.3390/ijms17010014. Special issue: Drug, herb, and dietary supplement hepatotoxicity.
    DOI  |   Google Scholar
  30. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.
    DOI  |   Google Scholar
  31. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53:750–5.
    DOI  |   Google Scholar
  32. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.
    DOI  |   Google Scholar
  33. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.
    DOI  |   Google Scholar
  34. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–6.
    DOI  |   Google Scholar
  35. 9. Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–30.
    DOI  |   Google Scholar
  36. M. Lazo, R. Hernaez, M. S. Eberhardt et al., “Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994,” American Journal of Epidemiology, vol. 178, no. 1, pp. 38–45, 2013.
    DOI  |   Google Scholar
  37. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004.
    DOI  |   Google Scholar
  38. A. Grieco, A. Forgione, L. Miele et al., “Fatty liver and drugs,” European Review for Medical and Pharmacological Sciences, vol. 9, no. 5, pp. 261–263, 2005.
     Google Scholar
  39. . W. Guglielmi, D. Boggio-Bertinet, A. Federico et al., “Total parenteral nutrition-related gastroenterological complications,” Digestive and Liver Disease, vol. 38, no. 9, pp. 623–642, 2006.
    DOI  |   Google Scholar
  40. Musso G., Gambino R., Cassader M.Non-alcoholic fatty liver disease from pathogenesis to management: an update Obes Rev, 11 (2010), pp. 430-445.
    DOI  |   Google Scholar
  41. Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis. 2003;7:435–51.
    DOI  |   Google Scholar
  42. Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44:34–87.
    DOI  |   Google Scholar
  43. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 1995;67:101–54.
    DOI  |   Google Scholar
  44. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta. 2011;412:1297–305.
    DOI  |   Google Scholar
  45. Kimura S, Kobayashi T, Tanaka Y, et al. Liver histopathology in clinical Reye syndrome. Brain Dev. 1991;13:95–100.
     Google Scholar
  46. Lammert C, Imler T, Teal E et al. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury. Clin Gastroenterol Hepatol. 2018; S1542-3565(18)31389-2.
     Google Scholar
  47. Tarantino G, Conca P, Basile V et al. A prospective studz of acute drug-induced liver injury in patients suffering from non-alcoholic liver disease. Hep Resarch 2007; 37: 410-415.
    DOI  |   Google Scholar
  48. Patel V, Sanyal AJ,. Drug-induced steatohepatitis. Clin Liver Dis. 2013 Nov; 17(4): 533–546
    DOI  |   Google Scholar
  49. Ćurguz A, Nežić L, Mandić M. Drug Induced Liver Injury: Pathogenesis, Clinical Features and Monitoring Scr Med 2016:47:140-147.
    DOI  |   Google Scholar
  50. Satapathy SK, kuwajima V, Nadelson J et al. Drug-induced fatty liver disease: An overview of pathogenesis and management. Annals of Hepatology2015; 14(6):789-806.
    DOI  |   Google Scholar
  51. Chen C, Krausz KW, Shah YM, Idle JR, Gonzalez FJ. Serum metabolomics reveals irreversible inhibition of fatty acidbeta-oxidation through the suppression of PPARalpha ac-tivation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol 2009; 22:699-707.
    DOI  |   Google Scholar
  52. Burcham PC, Harman AW. Acetaminophen toxicity resultsin site-specific mitochondrial damage in isolated mousehepatocytes. J Biol Chem 1991; 266: 5049-54.
    DOI  |   Google Scholar
  53. Freneaux E, romenty B, Berson A, Labbe G, Degott C,Letteron P, Larrey D, et al. Stereoselective and nonster-eoselective effects of ibuprofen enantiomers on mito-chondrial beta-oxidation of fatty acids. J Pharmacol ExpTher 1990; 255: 529-35.
     Google Scholar
  54. Moreno-Sanchez R, Bravo C, Vasquez C, Ayala G, SilveiraLH, Martinez-Lavin M. Inhibition and uncoupling of oxida-tive phosphorylation by nonsteroidal anti-inflammatorydrugs: study in mitochondria, submitochondrial parti-cles, cells, and whole heart. Biochem Pharmacol 1999;57: 743-52.
    DOI  |   Google Scholar
  55. Boelsterli UA. Diclofenac-induced liver injury: a paradigmof idiosyncratic drug toxicity. Toxicol Appl Pharmacol2003; 192: 307-22.
    DOI  |   Google Scholar
  56. Trost LC, Lemasters JJ. Role of the mitochondrial per-meability transition in salicylate toxicity to culturedrat hepatocytes: implications for the pathogenesis ofReye’s syndrome. Toxicol Appl Pharmacol 1997; 147:431-41.
    DOI  |   Google Scholar
  57. Deschamps D, Fisch C, Fromenty B, Berson A, Degott C,Pessayre D. Inhibition by salicylic acid of the activationand thus oxidation of long chain fatty acids. Possible rolein the development of Reye’s syndrome. J Pharmacol ExpTher 1991; 259: 894-904.
     Google Scholar
  58. Spaniol M, Bracher R, Ha HR, Follath F, Krähenbühl S. Tox-icity of amiodarone and amiodarone analogues on isolat-ed rat liver mitochondria. J Hepatol 2001; 35: 628-36.
    DOI  |   Google Scholar
  59. Kakuda TN. Pharmacology of nucleoside and nucleotidereverse transcriptase inhibitor-induced mitochondrialtoxicity. Clin Ther 2000; 22: 685-708.
    DOI  |   Google Scholar
  60. Silva MF, Aires CC, Luis PB, Ruiter JP, IJlst L, Duran M,Wanders RJ, et al. Valproic acid metabolism and its ef-fects on mitochondrial fatty acid oxidation: a review. JInherit Metab Dis 2008; 31: 205-16.
    DOI  |   Google Scholar
  61. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP,Nishimura Y, Crowe RA, et al. The mitochondrial permea-bility transition in cell death: a common mechanism innecrosis, apoptosis and autophagy. Biochim Biophys Acta1998; 1366: 177-96
    DOI  |   Google Scholar
  62. Larosche I, Letteron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, Pessayre D, et al. Tamoxifen inhibitstopoisomerases, depletes mitochondrial DNA, and triggerssteatosis in mouse liver. J Pharmacol Exp Ther 2007; 321:526-35.
    DOI  |   Google Scholar
  63. Labbe G, Pessayre D, Fromenty B. Drug-induced liver inju-ry through mitochondrial dysfunction: mechanisms and de-tection during preclinical safety studies. Fundam ClinPharmacol 2008; 22: 335-53.
    DOI  |   Google Scholar
  64. Grieco A, Forgione A, Miele L, Vero V, Greco AV, Gasbar-rini A, Gasbarrini G. Fatty liver and drugs. Eur Rev MedPharmacol Sci 2005; 9: 261-3.
     Google Scholar
  65. Sopher SM, Camm AJ. Adverse effects of amiodarone atlow dose: plus ca change. J Am Coll Cardiol 1997; 30:799-801.
     Google Scholar
  66. Kimura S, Kobayashi T, Tanaka Y, et al. Liver histopathology in clinical Reye syndrome. Brain Dev. 1991;13:95–100.
    DOI  |   Google Scholar
  67. Oh KW, Qian T, Brenner DA, et al. Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol Sci. 2003;73:44–52.
    DOI  |   Google Scholar
  68. Letteron P, Sutton A, Mansouri A, et al. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 2003;38:133–40.
    DOI  |   Google Scholar
  69. Freneaux E, Fromenty B, Berson A, et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids. J Pharmacol Exp Ther. 1990;255:529–35.
     Google Scholar
  70. 40. Victorino RM, Silveira JC, Baptista A, et al. Jaundice associated with naproxen. Postgrad Med J. 1980;56:368–70.
    DOI  |   Google Scholar
  71. Berends MA, van Oijen MG, Snoek J, et al. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol. 2007; 143:1515–9.
    DOI  |   Google Scholar
  72. 69. Hytiroglou P, Tobias H, Saxena R, et al. The canals of Hering might represent a target of methotrexate hepatic toxicity. Am J Clin Pathol. 2004;121:324–9. 70.
    DOI  |   Google Scholar
  73. Yamamoto N, Oliveira MB, de Campello AP, et al. Methotrexate: studies on the cellular metabolism. I. Effect on mitochondrial oxygen uptake and oxidative phosphorylation. Cell Biochem Funct. 1988;6:61–6.
    DOI  |   Google Scholar
  74. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol. 1996;24:200–8.
    DOI  |   Google Scholar


Most read articles by the same author(s)